The heterogeneous landscape of ALK negative ALCL

Elisabetta Mereu; Elisa Pellegrino; Irene Scarfò; Giorgio Inghirami; Roberto Piva

doi:10.18632/oncotarget.14503

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The heterogeneous landscape of ALK negative ALCL

Elisabetta Mereu, Elisa Pellegrino, Irene Scarfò, Giorgio Inghirami and Roberto Piva _

PDF | HTML | How to cite

Oncotarget. 2017; 8:18525-18536. https://doi.org/10.18632/oncotarget.14503

Metrics: PDF 2646 views | HTML 3610 views | ?

Abstract

Elisabetta Mereu1, Elisa Pellegrino1, Irene Scarfò2, Giorgio Inghirami1,3 and Roberto Piva1

1 Department of Molecular Biotechnology and Health Sciences, Center for Experimental Research and Medical Studies, University of Torino, Torino, Italy

2 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

3 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

Correspondence to:

Roberto Piva, email:

Keywords: anaplastic large cell lymphoma, molecular classification, therapy, ALK negative

Received: October 11, 2016 Accepted: December 27, 2016 Published: January 04, 2017

Abstract

Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients. A new revision of the World Health Organization (WHO) classification promoted ALK negative ALCL to a definite entity that includes cytogenetic subsets with prognostic implications. However, a further understanding of the genetic landscape of ALK negative ALCL is required to dictate more effective therapeutic strategies specifically tailored for each subgroup of patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14503

Publication Alerts

Reviews:

The heterogeneous landscape of ALK negative ALCL

Abstract